-
First Patient Dosed in Australia in ATG-101 First-in-Human Trial
prnasia
December 20, 2021
Antengene Corporation Limited ("Antengene", SEHK: 6996.HK), a leading innovative global biopharmaceutical company dedicated to discovering, developing and commercializing first-in-class and/or best-in-class therapeutics...
-
Antengene Receives FDA Approval of IND for Phase 1 Trial of ATG-101 (PD-L1/4-1BB bispecific antibody) in Solid Tumors and Non-Hodgkin Lymphoma
prnasia
November 01, 2021
Antengene Corporation Limited ("Antengene", SEHK: 6996.HK), a leading innovative global biopharmaceutical company dedicated to discovering, developing and commercializing first-in-class...
-
Antengene to Present Data of Its PD-L1/4-1BB Bispecific Antibody ATG-101 and ERK1/2 Inhibitor ATG-017 at SITC 2021
prnasia
October 15, 2021
The 36th Annual Meeting of the Society for Immunotherapy for Cancer (SITC 2021) will take place in Washington, D.C., United States, on November 10-14, 2021. The SITC's annual meeting is the world's largest gathering in the field of immuno-oncology.
-
Antengene Announces The Approval by Human Research Ethics Committee in Australia and to Start the Phase 1 Trial of ATG-101 (the first PD-L1/4-1BB bispecific antibody) in Solid Tumors and Non-Hodgkin L
prnasia
July 22, 2021
Antengene announced that the Bellberry Human Research Ethics Committee (HREC) in Australia has approved the clinical trial application of the phase 1 trial of ATG-101 in patients with metastatic/advanced solid tumors and B-cell non-Hodgkin's lymphoma.
-
Antengene Announces the Completion of the Quantitative and Systems Pharmacology Modeling for ATG-101 in Preparation for First-in-Human Trial
prnasia
May 17, 2021
Antengene today announced ATG-101, a novel PD-L1/4-1BB bispecific antibody being developed by the company, has completed its quantitative and systems pharmacology (QSP) modeling that will provide data guiding the first-in-human study of ATG-101.